The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT.
Date
2024-04-01ICR Author
Author
Hwang, A
Hayden, P
Pawlyn, C
McLornan, D
Garderet, L
Type
Journal Article
Metadata
Show full item recordAbstract
Recent treatment advancements in multiple myeloma have led to significant improvements in patient outcomes. Maintenance therapy following autologous haematopoietic stem cell transplantation (AHCT) is now standard of care and has been demonstrated to prolong and deepen treatment responses. Currently, lenalidomide remains the single agent that has been approved for maintenance post-AHCT in Europe and the USA which, if tolerated, is continued until disease progression. The treatment landscape is rapidly expanding however, and the optimal personalised maintenance approach for a patient is becoming more complex. Treatment outcomes for patients with high-risk disease remain poor and choice of maintenance in this population also remains unclear. This review article evaluates up-to-date literature regarding established maintenance approaches. It further analyses ongoing studies exploring maintenance regimens using combination and novel agents, approaches to maintenance in patients with cytogenetic high-risk disease and minimal residual disease response-adapted strategies that reflect the current evolving treatment paradigm.
Collections
Subject
BMT
maintenance therapy
multiple myeloma
myeloma therapy
stem cell transplantation
Humans
Multiple Myeloma
Hematopoietic Stem Cell Transplantation
Transplantation, Autologous
Lenalidomide
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols
Stem Cell Transplantation
Research team
Myeloma Biol Therap
Language
eng
Date accepted
2024-02-12
License start date
2024-04-01
Citation
British Journal of Haematology, 2024, 204 (4), pp. 1159 - 1175
Publisher
WILEY
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by-nc/4.0
Related items
Showing items related by title, author, creator and subject.
-
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
Dirksen, U; Brennan, B; Le Deley, M-C; Cozic, N; van den Berg, H; et al. (2019-12)PURPOSE:The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end ... -
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
Craddock, C; Slade, D; De Santo, C; Wheat, R; Ferguson, P; et al. (AMER SOC CLINICAL ONCOLOGY, 2019-03-01)PURPOSE: Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required. ... -
MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.
Brown, S; Sherratt, D; Hinsley, S; Flanagan, L; Roberts, S; et al. (BMJ PUBLISHING GROUP, 2021-03-24)INTRODUCTION: Multiple myeloma (MM) is a plasma cell tumour with over 5800 new cases each year in the UK. The introduction of biological therapies has improved outcomes for the majority of patients with MM, but in approximately ...